Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Sigma Healthcare Ltd ( (AU:SIG) ).
Sigma Healthcare has disclosed a change in the interests of director Mario Verrocchi, who has been granted 314,021 rights to acquire fully paid ordinary shares under the company’s 2025 Long Term Incentive Plan, approved at its 2025 annual general meeting. The performance rights, issued for nil consideration as part of Verrocchi’s remuneration package, increase his direct holdings to include these 2025 LTI rights in addition to his existing substantial direct and indirect shareholdings, underscoring Sigma’s continued use of equity-based incentives to align executive interests with those of shareholders.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.39 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
More about Sigma Healthcare Ltd
Sigma Healthcare Limited is an Australian company operating in the healthcare and pharmaceutical sector, listed on the ASX. The company is involved in the distribution of pharmaceutical products and related healthcare services, and it uses long term incentive plans as part of its executive and employee remuneration framework.
Average Trading Volume: 15,600,081
Technical Sentiment Signal: Buy
Current Market Cap: A$33.53B
Learn more about SIG stock on TipRanks’ Stock Analysis page.